Proline-directed protein kinase FA as a potential target for diagnosis and therapy of human cancers

Current Cancer Drug Targets

Volumn 4, Issue 7, 2004, Pages 591-596

  Yang, Shiaw Der ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Chemoresistance; Differentiation; Invasion; Metastasis; PDPK FA; Poor prognosis; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; PROLINE DIRECTED PROTEIN KINASE;

APOPTOSIS; CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CHEMOSENSITIVITY; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NEOPLASM; NONHUMAN; PATHOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROLINE-DIRECTED PROTEIN KINASES;

EID: 8844250081     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332817     Document Type: Review

References (65)

1. Yang, S. D.; Vandenheede, J. R.; Goris, J.; Merlevede, W. ATP·Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the enzyme and its regulation by the interaction with an activating protein factor. J. Biol. Chem. 1980, 255, 11759-11767.
2. Vandenheede, J. R.; Yang, S. D.; Goris, J.; Merlevede, W. ATP·Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. J. Biol. Chem. 1980, 255, 11768-11774.
3. 404-Pro that are abnormally phosphorylaled in Alzheimer's disease brain. J. Neurochem. 1993, 61, 1742-1747.
4. A/glycogen synthase kinase-3α after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain. J. Neurochem. 1994, 63, 1416-1425.
5. 97-Pro in brain myelin basic protein: evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs. J. Neurochem. 1994, 62, 1596-1603.
6. 666 in neurofilament. J. Neurochem. 1995, 64, 1848-1854.
7. A). Adv. Prot. Phosphatase. 1991, 6, 133-157.
8. A/GSK-3α). J. Chin. Biochem. Soc. 1994, 23, 123-134.
9. He, X.; Saint-Jeannet, J. P.; Woodgett, J. R.; Varmus, H. E.; Dawid, I. B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995, 374, 617-622.
10. Embi, N.; Rylatt, D. B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107, 519-527.
11. A) of the (Mg·ATP) dependent protein phosphatase. Eur. J. Biochem. 1981, 119, 443-451.
12. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9, 2431-2438.
13. Woodgett, J. R. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2003, 3, 281-290.
14. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116, 1175-1186.
15. Manoukian, A. S.; Woodgett, J. K. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 2002, 84, 203-229.
16. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3, 479-487.
17. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003, 423, 435-439.
18. A/GSK-3α correlates with human thyroid tumor cell dedifferentiation. J. Cell Biochem. 1995, 58, 474-480.
19. A/GSK-3α (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression. J. Cell Biochem. 1995, 59, 143-150.
20. A/GSK- 3α (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J. Cell Biochem. 1996, 61, 238-245.
21. A enhances chemosensitivity in human prostate cancer cells. Clin. Cancer Res. 2000, 6, 1024-1030.
22. A with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer 2002, 95, 1840-1847.
23. A with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer 2002, 95, 775-783.
24. A inhibits the malignant growth of human pancreatic ductal adenocarcinoma. Anticancer Res. 2004, 24, 1489-1494.
25. A expression inhibits the growth of human chronic myeloid leukaemia cells. Br. J. Cancer 2000, 82, 1480-1484.
26. A systemically inhibits the growth of human acute leukemia cells. Int. J. Cancer 2001, 91, 650-653.
27. A potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells. Cancer 2001, 92, 1753-1758.
28. A expression potentiates erythroid differentiation of human myeloid leukemia cells. Cancer 2000, 89, 1004-1011.
29. Shaw, P. C.; Davies, A. F.; Lau, K. F.; Garcia-Barcelo, M.; Waye, M. M.; Lovestone, S.; Miller, C. C.; Anderton, B. H. Isolation and chromosomal mapping of human glycogen synthase kinase-3α and -3β encoding genes. Genome 1998, 41, 720-727.
30. Lau, K. F.; Miller, C. C.; Anderton, B. H.; Shaw, P. C. Expression analysis of glycogen synthase kinase-3 in human tissues. J. Pept. Res. 1999, 54, 85-91.
31. Lau, K. F.; Miller, C. C.; Anderton, B. H.; Shaw, P. C. Molecular cloning and characterization of the human glycogen synthase kinase-3β promoter. Genomics 1999, 60, 121-128.
32. Lee, K. F.; Chan, J. Y.; Lau, K. F.; Lee, W. C.; Miller, C. C.; Anderton, B. H.; Shaw, P. C. Molecular cloning and expression analysis of human glycogen synthase kinase-3α promoter. Brain Res. Mol. Brain Res. 2000, 84, 150-157.
33. Bast, R. C. Jr.; Ravdin, P.; Hayes, D. F.; Bates, S.; Fritsche, H. Jr.; Jessup, J. M.; Kemeny, N.; Locker, G. Y.; Mennel, R. G.; Somerfield, M. R. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001, 19, 1865-1878.
34. Compton, C.; Fenoglio-Preiser, C. M.; Pettigrew, N.; Fielding, L. P. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000, 88, 1739-1757.
35. Gennari, L.; Doci, R.; Rossetti, C. Prognostic factors in colorectal cancer. Hepatogastroenterology 2000, 47, 310-314.
36. Midgley, R.; Kerr, D. Colorectal cancer. Lancet 1999, 353, 391-399.
37. Bresalier, R. S.; Ho, S. B. Molecular staging of colorectal cancer: a step forward. Gastroenterology 1999, 116, 769.
38. Vogelstein, B.; Fearon, E. R.; Hamilton, S. R.; Kern, S. E.; Preisinger, A. C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A. M.; Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319, 525-532.
39. Deans, G. T.; Parks, T. G.; Rowlands, B. J.; Spence, R. A. Prognostic factors in colorectal cancer. Br. J. Surg. 1992, 79, 608-613.
40. Beahrs, O. H. Colorectal cancer staging as a prognostic feature. Cancer 1982, 50, 2615-2617.
41. Fielding, L. P.; Phillips, R. K.; Fry, J. S.; Hittinger, R. Prediction of outcome after curative resection for large bowel cancer. Lancet 1986, 2, 904-907.
42. Bouzourene, H.; Gervaz, P.; Cerottini, J. P.; Benhattar, J.; Chaubert, P.; Saraga, E.; Pampallona, S.; Bosman, F. T.; Givel, J. C. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur. J. Cancer 2000, 36, 1008-1015.
43. Wolmark, N.; Fisher, B.; Wieand, H. S. The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials. Ann. Surg. 1986, 203, 115-122.
44. Srivastava, S.; Verma, M.; Henson, D. E. Biomarkers for early detection of colon cancer. Clin. Cancer Res. 2001, 7, 1118-1126.
45. Fahy, B.; Bold, R. J. Epidemiology and molecular genetics of colorectal cancer. Surg. Oncol. 1998, 7, 115-123.
46. Droller, M. J. Bladder cancer: state-of-the-art care. CA Cancer J. Clin. 1998, 45, 269-284.
47. Lamm, D. L. Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J. Clin. 1998, 48, 263-268.
48. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78, 539-542.
49. Chessells, J. M. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br. J. Haematol. 1998, 102, 423-438.
50. Finiewicz, K. J.; Larson, R. A. Dose-intensive therapy for adult acute lymphoblastic leukemia. Semin. Oncol. 1999, 26, 6-20.
51. Pawinski, A.; Sylvester, R.; Kurth, K. H.; Bouffioux, C.; van der Meijden, A.; Parmar, M. K.; Bijnens, L. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaTl bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 1996, 156, 1934-1940.
52. Nilsson, S.; Ragnhammar, P.; Glimelius, B.; Nygren, P. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol. 2001, 40, 371-390.
53. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999, 354, 533-540.
54. Duque, J. L.; Loughlin, K. R. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol. Clin. North Am. 2000, 27, 125-135.
55. Hart, I. R.; Goode, N. T.; Wilson, R. E. Molecular aspects of the metastatic cascade. Biochim. Biophys. Acta 1989, 989, 65-84.
56. Hart, I. R.; Saini, A. Biology of tumour metastasis. Lancet 1992, 339, 1453-1457.
57. Van Roy, F.; Mareel, M. Tumour invasion: effects of cell adhesion and motility. Trends Cell Biol. 1992, 2, 163-169.
58. Tang, D. G.; Honn, K. V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994, 14, 109-122.
59. Jothy, S.; Munro, S. B.; LeDuy, L.; McClure, D.; Blaschuk, O. W. Adhesion or anti-adhesion in cancer: what matters more? Cancer Metastasis Rev. 1995, 14, 363-376.
60. Nicolson, G. L. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988, 7, 143-188.
61. Matsumura, Y.; Tarin, D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992, 340, 1053-1058.
62. Schumacher, U.; Higgs, D.; Loizidou, M.; Pickering, R.; Leathem, A.; Taylor, I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer 1994, 74, 3104-3107.
63. Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 1999, 76, 1-20.
64. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
65. Dancey, J.; Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2003, 2, 296-313.